The estimated Net Worth of Dean Slagel is at least $9.42 Million dollars as of 29 June 2017. Dean Slagel owns over 250,000 units of Cara Therapeutics Inc stock worth over $308,658 and over the last 11 years Dean sold CARA stock worth over $9,107,826.
Dean has made over 3 trades of the Cara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Dean sold 250,000 units of CARA stock worth $6,467,500 on 29 June 2017.
The largest trade Dean's ever made was selling 250,000 units of Cara Therapeutics Inc stock on 29 June 2017 worth over $6,467,500. On average, Dean trades about 53,646 units every 86 days since 2014. As of 29 June 2017 Dean still owns at least 1,064,338 units of Cara Therapeutics Inc stock.
You can see the complete history of Dean Slagel stock trades at the bottom of the page.
Dean's mailing address filed with the SEC is C/O ESPERANTE AB, PO BOX 30127, LIMHAMN, V7, SE-20061.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, and Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: